InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

- Current share price for MSB : $2.160

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,811 Appendix 4G and Corporate Governance Statement 30 Oct 2023 8:55AM $0.365 $2.160 risen by 491.78%
$2,811 Notification of cessation of securities - MSB 16 Oct 2023 8:26PM $0.360 $2.160 risen by 500%
$2,811 Notification regarding unquoted securities - MSB 16 Oct 2023 8:24PM $0.360 $2.160 risen by 500%
$2,811 Final Director's Interest Notice 29 Sep 2023 5:01PM $0.390 $2.160 risen by 453.85%
$2,811 Jane Bell Appointed Chair of Audit and Risk Committee 26 Sep 2023 10:25AM $0.370 $2.160 risen by 483.78%
$2,811 Mesoblast Type A Meeting with FDA 21 Sep 2023 10:09AM $0.385 $2.160 risen by 461.04%
$2,811 MSB Annual Financial Results and Operational Update 31 Aug 2023 8:20AM $0.455 $2.160 risen by 374.73%
$2,811 Annual Financial Results Presentation 31 Aug 2023 8:17AM $0.455 $2.160 risen by 374.73%
$2,811 Preliminary Final Report including Appendix 4E 31 Aug 2023 8:08AM $0.455 $2.160 risen by 374.73%
$2,811 Mesoblast 2023 Full Year Financial Results Webcast 29 Aug 2023 5:53PM $0.455 $2.160 risen by 374.73%
$2,811 Change in substantial holding 29 Aug 2023 9:17AM $0.440 $2.160 risen by 390.91%
$2,811 Ceasing to be a substantial holder 11 Aug 2023 8:18AM $0.370 $2.160 risen by 483.78%
$2,811 Ceasing to be a substantial holder 10 Aug 2023 8:12AM $0.350 $2.160 risen by 517.14%
$2,811 Change in substantial holding 10 Aug 2023 8:12AM $0.350 $2.160 risen by 517.14%
$2,811 Change in substantial holding 9 Aug 2023 8:21AM $0.375 $2.160 risen by 476%
$2,811 Change in substantial holding 9 Aug 2023 8:21AM $0.375 $2.160 risen by 476%
$2,811 Update on BLA for Graft Versus Host Disease 4 Aug 2023 9:57AM $1.090 $2.160 risen by 98.17%
$2,811 Change in substantial holding 3 Aug 2023 8:18AM $1.090 $2.160 risen by 98.17%
$2,811 Trading Halt 2 Aug 2023 8:41AM $1.090 $2.160 risen by 98.17%
$2,811 Change in substantial holding 1 Aug 2023 8:12AM $1.145 $2.160 risen by 88.65%
$2,811 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2023 9:49AM $1.150 $2.160 risen by 87.83%
$2,811 Appendix 3G, Appendix 3H and Appendix 3Ys 7 Jul 2023 5:22PM $1.130 $2.160 risen by 91.15%
$2,811 Change of Director's Interest Notice 13 Jun 2023 8:56AM $1.025 $2.160 risen by 110.73%
$2,811 Mesoblast Director Appointed to Strategic Advisory Role 5 Jun 2023 9:41AM $1.065 $2.160 risen by 102.82%
$2,811 MSB Reports Q3 Financial Results and Operational Highlights 26 May 2023 8:32AM $1.040 $2.160 risen by 107.69%

351 - 375 of 1203 results

Page 15 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.